Clinical trials and Cancer, the lessons, paradoxes and positives

Tue, 10/12/2010 - 1:20pm
3B Nexus

Investor, Andy Smith, reviews some of the learnings from cancer clinical trials and examples of what investors have learnt from compounds in development and a paradox in oncology clinical trials. Companies mentioned in this talk will include AstraZeneca, OSI Pharma and Antisoma.

Continuing a series of expert analysis and commentary on the Healthcare sector. Join the discussion and leave your comments and feedback for more on this and other upcoming Global Healthcare sector topics.

You need to upgrade your Flash Player!

This web site makes use of the Macromedia Flash player 8.

VIDEO PLAYER by 3b nexus

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.